304 related articles for article (PubMed ID: 32142667)
1. Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.
Zheng ZY; Anurag M; Lei JT; Cao J; Singh P; Peng J; Kennedy H; Nguyen NC; Chen Y; Lavere P; Li J; Du XH; Cakar B; Song W; Kim BJ; Shi J; Seker S; Chan DW; Zhao GQ; Chen X; Banks KC; Lanman RB; Shafaee MN; Zhang XH; Vasaikar S; Zhang B; Hilsenbeck SG; Li W; Foulds CE; Ellis MJ; Chang EC
Cancer Cell; 2020 Mar; 37(3):387-402.e7. PubMed ID: 32142667
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
3. High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Traphagen NA; Hosford SR; Jiang A; Marotti JD; Brauer BL; Demidenko E; Miller TW
Oncogene; 2021 May; 40(19):3408-3421. PubMed ID: 33875787
[TBL] [Abstract][Full Text] [Related]
4. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
[TBL] [Abstract][Full Text] [Related]
5. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
6. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
7. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
8. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
[TBL] [Abstract][Full Text] [Related]
9. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
10. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
11. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
12. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
13. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
14. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
[TBL] [Abstract][Full Text] [Related]
17. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Sharma D; Saxena NK; Davidson NE; Vertino PM
Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
[TBL] [Abstract][Full Text] [Related]
18. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
19. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
